Tags

Type your tag names separated by a space and hit enter

The risk and outcomes of pneumonia in patients on inhaled corticosteroids.
Pulm Pharmacol Ther. 2015 Jun; 32:130-6.PP

Abstract

Corticosteroids are frequently prescribed anti-inflammatory medications. Inhaled corticosteroids (ICS) are indicated for Chronic Obstructive Pulmonary Disease (COPD) and asthma. ICS are associated with a decrease in exacerbations and improved quality of life in COPD, however multiple studies have linked the chronic use of ICSs with an increased risk of developing pneumonia, though the effect on mortality is unclear. We review the association of ICS with the risk of pneumonia and the implications on clinical outcomes.

Authors+Show Affiliations

Servei de Pneumologia, Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret 167, 08025 Barcelona, Spain; Institut d'Investigació Biomèdica Sant Pau (IBB Sant Pau), Sant Antoni Maria Claret, 167 Pavelló de Sant Frederic, Planta 1, 08025 Barcelona, Spain. Electronic address: OSibila@santpau.cat.South Texas Veterans Health Care System, 7400 Merton Minter Boulevard, San Antonio, TX 78229, United States; University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229, United States. Electronic address: sotogomez@uthscsa.edu.South Texas Veterans Health Care System, 7400 Merton Minter Boulevard, San Antonio, TX 78229, United States; University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229, United States. Electronic address: restrepom@uthscsa.edu.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Review

Language

eng

PubMed ID

25956073

Citation

Sibila, Oriol, et al. "The Risk and Outcomes of Pneumonia in Patients On Inhaled Corticosteroids." Pulmonary Pharmacology & Therapeutics, vol. 32, 2015, pp. 130-6.
Sibila O, Soto-Gomez N, Restrepo MI. The risk and outcomes of pneumonia in patients on inhaled corticosteroids. Pulm Pharmacol Ther. 2015;32:130-6.
Sibila, O., Soto-Gomez, N., & Restrepo, M. I. (2015). The risk and outcomes of pneumonia in patients on inhaled corticosteroids. Pulmonary Pharmacology & Therapeutics, 32, 130-6. https://doi.org/10.1016/j.pupt.2015.04.001
Sibila O, Soto-Gomez N, Restrepo MI. The Risk and Outcomes of Pneumonia in Patients On Inhaled Corticosteroids. Pulm Pharmacol Ther. 2015;32:130-6. PubMed PMID: 25956073.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The risk and outcomes of pneumonia in patients on inhaled corticosteroids. AU - Sibila,Oriol, AU - Soto-Gomez,Natalia, AU - Restrepo,Marcos I, Y1 - 2015/05/05/ PY - 2014/11/24/received PY - 2015/04/16/revised PY - 2015/04/24/accepted PY - 2015/5/10/entrez PY - 2015/5/10/pubmed PY - 2016/3/22/medline KW - Chronic obstructive pulmonary disease KW - Inhaled corticosteroids KW - Pneumonia SP - 130 EP - 6 JF - Pulmonary pharmacology & therapeutics JO - Pulm Pharmacol Ther VL - 32 N2 - Corticosteroids are frequently prescribed anti-inflammatory medications. Inhaled corticosteroids (ICS) are indicated for Chronic Obstructive Pulmonary Disease (COPD) and asthma. ICS are associated with a decrease in exacerbations and improved quality of life in COPD, however multiple studies have linked the chronic use of ICSs with an increased risk of developing pneumonia, though the effect on mortality is unclear. We review the association of ICS with the risk of pneumonia and the implications on clinical outcomes. SN - 1522-9629 UR - https://www.unboundmedicine.com/medline/citation/25956073/The_risk_and_outcomes_of_pneumonia_in_patients_on_inhaled_corticosteroids_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1094-5539(15)00043-7 DB - PRIME DP - Unbound Medicine ER -